Capital Partners Ii, Llc Ta... Net Worth

The estimated Net Worth of Capital Partners Ii, Llc Ta... is at least 195 千$ dollars as of 25 June 2018. Capital Ta owns over 150,000 units of Aptinyx Inc stock worth over 194,595$ and over the last 8 years Capital sold APTX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Ta APTX stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Aptinyx Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 150,000 units of APTX stock worth 2,400,000$ on 25 June 2018.

The largest trade Capital's ever made was buying 150,000 units of Aptinyx Inc stock on 25 June 2018 worth over 2,400,000$. On average, Capital trades about 75,000 units every 0 days since 2016. As of 25 June 2018 Capital still owns at least 3,190,079 units of Aptinyx Inc stock.

You can see the complete history of Capital Ta stock trades at the bottom of the page.

Insiders trading at Aptinyx Inc

Over the last 6 years, insiders at Aptinyx Inc have traded over 0$ worth of Aptinyx Inc stock and bought 10,337,357 units worth 55,328,087$ . The most active insiders traders include Street Partners Llc Adams、Patrick G Enright、James N Topper. On average, Aptinyx Inc executives and independent directors trade stock every 35 days with the average trade being worth of 18,161$. The most recent stock trade was executed by Joan W. Miller on 13 January 2022, trading 17,700 units of APTX stock currently worth 50,091$.

What does Aptinyx Inc do?

welcome to our company page and thank you for your interest in aptinyx inc. aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the nmda receptor to enhance pathways involved with nerve cell communication. our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. at aptinyx, we remain committed and responsive to our employees. we offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. if you are interested in learning more, please visit our website at www.aptinyx.com.

Complete history of Capital Ta stock trades at Aimmune Therapeutics Inc、Aptinyx Inc

Aptinyx Inc executives and stock owners

Aptinyx Inc executives and other stock owners filed with the SEC include:

• Norbert Riedel,
  President, Chief Executive Officer, Director
• Ashish Khanna,
  Chief Financial Officer, Chief Business Officer
• Andrew Kidd,
  Chief Operating Officer
• Dr. Norbert G. Riedel,
  Exec. Chairman
• Dr. Andrew D. Kidd B.M. B.Ch., M.D.,
  CEO, Pres & Director
• Ashish Khanna,
  CFO & Chief Bus. Officer
• Henry Gosebruch,
  Independent Director
• Rachel Sherman,
  Independent Director
• Robert Hombach,
  Independent Director
• Patrick Enright,
  Independent Chairman of the Board
• Adam Koppel,
  Independent Director
• Elisha Gould,
  Independent Director
• Tim Noffke,
  VP of Program Management & Chief of Staff
• Dr. Harald Murck M.D., Ph.D.,
  VP of Clinical & Medical Affairs
• Patrick Flavin,
  Sr. Mang. of Corp. Devel. & Investor Relations
• Dr. Kathryn King Ph.D.,
  Sr. VP of Clinical & CMC Operations
• Molly Dir,
  VP of HR
• Juan Estupinan,
  VP of Fin. & Accounting and Controller
• Capital Life Sciences Inves...,
  
• Gilmore Neil O'neill,
  
• Terry P Gould,
  
• Leaf Venture Management Iii...,
  
• David Houck,
  Chief Development Officer
• Torsten M. Madsen,
  Chief Medical Officer
• James N Topper,
  Director
• Life Sciences Viii, L.P.Fhm...,
  
• Capital Partners Ii, Llc Ta...,
  
• Wilbur H Gantz,
  Director
• Joseph R. Moskal,
  Chief Scientific Officer
• Street Partners Llc Adams,
  10% owner
• Liam Ratcliffe,
  Director
• Joan W. Miller,